Bank of America Issues Pessimistic Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE) had its price objective cut by analysts at Bank of America from $29.00 to $28.00 in a report issued on Monday,Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Bank of America‘s price target indicates a potential upside of 8.27% from the company’s current price.

Other analysts have also recently issued reports about the stock. HSBC restated a “buy” rating and set a $29.00 price target on shares of Pfizer in a report on Wednesday. Sanford C. Bernstein reissued a “market perform” rating and set a $30.00 target price on shares of Pfizer in a research note on Friday, October 31st. Morgan Stanley dropped their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.22.

Pfizer Stock Performance

Shares of PFE stock opened at $25.86 on Monday. The company has a market capitalization of $147.04 billion, a price-to-earnings ratio of 15.04 and a beta of 0.46. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. The stock’s fifty day simple moving average is $25.12 and its 200-day simple moving average is $24.78.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently made changes to their positions in PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the 1st quarter valued at approximately $27,000. Curio Wealth LLC grew its stake in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth $28,000. Grey Fox Wealth Advisors LLC acquired a new position in Pfizer during the 3rd quarter worth $29,000. Finally, Harbor Asset Planning Inc. bought a new stake in Pfizer during the second quarter valued at about $29,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.